Full-Time
Posted on 7/31/2024
Produces synthetic DNA for biotechnology applications
$202k - $249k/yr
Senior, Expert
Oakland, CA, USA
Field-based role in San Francisco Bay Area, CA.
Upload your resume to see how it matches 14 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Twist Bioscience specializes in the synthesis of synthetic DNA, which is essential for various applications in biotechnology, pharmaceuticals, and research. The company produces high-quality DNA sequences that clients, including academic institutions and pharmaceutical companies, use for developing new drugs, diagnosing diseases, and conducting genetic research. Twist Bioscience differentiates itself by offering competitive pricing and a proprietary platform that allows for quick and accurate DNA production. This platform utilizes a smart algorithm to provide instant feedback on the synthesizability of DNA sequences. Their product range includes genes, oligo pools, variant libraries, and tools for SARS-CoV-2, along with DNA data storage and next-generation sequencing services. The company's goal is to be a leading supplier in the synthetic biology market, providing thousands of genes rapidly and effectively, thus supporting a wide array of research projects.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.